Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Number 9—September 2017
Research

Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, Australia

David WhileyComments to Author , Ella Trembizki, Cameron Buckley, Kevin Freeman, Robert W. Baird, Miles Beaman, Marcus Y. Chen, Basil Donovan, Ratan L. Kundu, Christopher K. Fairley, Rebecca Guy, Tiffany Hogan, John M. Kaldor, Mahdad Karimi, Athena Limnios, David G. Regan, Nathan Ryder, Jiunn-Yih Su, James Ward, and Monica M. Lahra
Author affiliations: Pathology Queensland Central Laboratory, Brisbane, Queensland, Australia (D. Whiley); The University of Queensland, Brisbane (D. Whiley, E. Trembizki, C. Buckley); Royal Darwin Hospital, Darwin, Northern Territory, Australia (K. Freeman, R.W. Baird); University of Western Australia, Nedlands, Western Australia, Australia (M. Beaman); University of Notre Dame Australia, Fremantle, Western Australia, Australia (M. Beaman); Western Diagnostic Pathology, Perth, Western Australia, Australia (M. Beaman, M. Karimi); Alfred Health, Carlton, Victoria, Australia (M. Chen, C.K. Fairley); Central Clinical School, Monash University, Melbourne, Victoria, Australia (M. Chen, C.K. Fairley); Sydney Hospital, Sydney, New South Wales, Australia (B. Donovan); University of New South Wales, Sydney (B. Donovan, R. Guy, J.M. Kaldor, D.G. Regan, N. Ryder, M.M. Lahra); Prince of Wales Hospital, Sydney (R.L. Kundu, T. Hogan, A. Limnios, M.M. Lahra); School of Medical Sciences, Hunter New England Local Health District, Sydney (N. Ryder); Menzies School of Health Research and Charles Darwin University, Darwin (J.-Y. Su); South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia (J. Ward); Flinders University, Adelaide (J. Ward)

Main Article

Table 1

PCR results for the 1,629 NAAT-positive Neisseria gonorrhoeae clinical samples taken from patients in the Northern Territory of Australia, 2014*

Assay and targets
 Results
CAZ region, n = 441
ZAP region, n = 1,188
Total for both regions, n = 1,629
No. samples/no. tested
 % Samples (95% CI)
 No. samples/no. tested
 % Samples (95% CI)
 No. samples/no. tested
 % Samples (95% CI)
GyrA91-PCR (gyrA)
Wild type (S91) 235/297 79.1 (74.1–83.4) 922/931 99.0 (98.2–99.5) 1,157/1,228 94.2 (92.8–95.4)
S91F 62/297 20.9 (16.6–25.9) 9/931 1.0 (0.5–1.8) 71/1,228 5.8 (4.6–7.2)
Uncharacterized†
 144
 32.6
257
 21.6
401/1,629
 24.6
PPNG-PCR
Negative 252/286 88.1 (83.8–91.4) 879/888 99 (98.1–99.5) 1,131/1,174 96.3 (95.1–97.3)
PPNG 34/286 11.9 (8.6–16.2) 9/888 1 (0.5–1.9) 43/1,174 3.7 (2.7–4.9)
Uncharacterized†
 155
 35.1
300
 25.3
455/1,629
 27.9
2611-PCR (23S rRNA)
Wild type 321/321 100 (98.8–100) 958/960 99.8 (99.2–99.9) 1,279/1,281 99.8 (99.4–100)
C2611T 0/321 0 (0–1.2) 2/960 0.2 (0.1–0.8) 2/1,281 0.2 (0–0.6)
Uncharacterized†
 120
 27.2
228
 19.2
348/1,629
 21.4
2059-PCR (23S rRNA)
Wild type 319/319 100 (98.8–100) 1,004/1,004 100 (99.6–100) 1,323/1,323 100 (99.7–100)
A2059G 0/319 0 (0–1.2) 0/1,004 0 (0–0.4) 0/1,323 0 (0–0.3)
Uncharacterized†
 122
 27.7
184
 15.5
306/1,629
 18.8
PorB-PCR (porB)
G101/A102 98/286 34.3 (29–39.9) 125/835 15.0 (12.7–17.6) 223/1,121 19.9 (17.7–22.3)
[G101/A102, non-PPNG]‡ [80/280] [28.6 (23.4–34.1)] [116/823] [14.1 (11.9–16.6)] [196/1,103] [17.8 (15.6–20.1)]
PorB1a 152/286 53.1 (47.4–58.9) 699/835 83.7 (81.1–86.1) 851/1,121 75.9 (73.3–78.3)
[PorB1a, non-PPNG]‡ [120/267] [44.9 (39.1–50.9)] [627/770] [81.3 (78.4–83.9)] [747/1,037] [72.0 (69.2–74.7)]
Mutant§ 32/286 11.2 (8–15.4) 3/835 0.4 (0.1–1.1) 35/1,121 3.1 (2.3–4.3)
PorB1a and G101/A102 4/286 1.4 (0.5–3.5) 6/835 0.7 (0.3–1.6) 10/1,121 0.9 (0.5–1.6)
PorB1a and mutant§ 0/286 0 (0–1.3) 2/835 0.2 (0.1–0.9) 2/1,121 0.2 (0–0.6)
Uncharacterized†
 155
 35.1
353
 29.8
508/1,629
 31.2
A-deletion-PCR (MtrR)
Wild type 280/318 88.1 (84–91.2) 944/950 99.4 (98.6–99.7) 1,224/1,268 96.5 (95.4–97.4)
[Wild type, non-PPNG]‡ [226/284] [79.6 (74.5–84.1)] [861/873] [98.6 (97.6–99.2)] [1,087/1,157] [93.9 (92.4–95.2)]
A-deletion 38/318 11.9 (8.8–16) 6/950 0.6 (0.3–1.4) 44/1268 3.5 (2.6–4.6)
Uncharacterized†
 123
 27.9
238
 20
361/1629
 22.2
mosaicPBP2-PCR (penA)
Negative 431/441 97.7 (95.9–98.8) 1,188/1,188 100 (99.7–100) 1,619/1,629 99.4 (98.9–99.7)
Positive 10/441 2.3 (1.2–4.1) 0/1188 0 (0–0.3) 10/1,629 0.6 (0.3–1.1)
Uncharacterized†¶
 NA
 NA
NA
 NA
NA
 NA
A8806-PCR (penA)
Negative 441/441 100 (99.1–100) 1,188/1,188 100 (99.7–100) 1,629/1,629 100 (99.8–100)
Positive 0/441 0 (0–0.9) 0/1,188 0 (0–0.3) 0/1,629 0 (0–0.2)
Uncharacterized†¶ NA NA NA NA NA NA

*NA, not applicable; NAAT, nucleic acid amplification test; PPNG, penicillinase-producing N. gonorrhoeae.
†These samples could not be characterized by the respective PCR assay.
‡These PorB-PCR and A-deletion-PCR results were combined with the PPNG-PCR results to exclude those that were PPNG. Uncharacterized PPNG-PCR results were omitted from total numbers.
§Mutant = G101K/A102D, G101K/A102N or G101K/A102G.
¶All negative results for the mosaicPBP2-PCR and A8806-PCR were considered valid (i.e., characterized) given that pooled samples were used for screening, and it was therefore not possible to ascertain characterization for individual samples.

Main Article

Page created: August 14, 2017
Page updated: August 14, 2017
Page reviewed: August 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external